Michael J. Fox Foundation

Michael J. Fox Foundation
source
Name	Michael J. Fox Foundation
Founded	0 2000
Founder	Michael J. Fox
Key people	Michael J. Fox, Deborah W. Brooks
Focus	Parkinson's disease research
Location	New York City, New York, United States
Website	https://www.michaeljfox.org

Michael J. Fox Foundation. The Michael J. Fox Foundation is a prominent nonprofit organization dedicated to accelerating the development of improved therapies and ultimately finding a cure for Parkinson's disease. Founded in 2000 by the acclaimed actor and advocate Michael J. Fox, who was diagnosed with the condition in 1991, the foundation has become the world's largest nonprofit funder of Parkinson's research. Its strategy emphasizes high-risk, high-reward science, patient-centric research priorities, and efficient project management to bridge the translational gap between laboratory discoveries and clinical applications for patients.

History and founding

The foundation was established by Michael J. Fox following his public disclosure of his 1991 diagnosis with young-onset Parkinson's disease and his subsequent retirement from full-time acting on the television series Spin City. Driven by a personal mission to drive progress against the neurodegenerative disorder, Fox leveraged his public platform and partnered with Deborah W. Brooks, a former Goldman Sachs executive, to create a uniquely focused and business-like research organization. Initial operations were supported by proceeds from Fox's memoir, Lucky Man, and the organization quickly gained significant support from philanthropic donors and the broader Parkinson's disease community. Its creation coincided with a period of growing scientific understanding of the genetics and pathology of the disease, positioning it to strategically fund emerging areas of promise.

Mission and research focus

The core mission is to eliminate Parkinson's disease through an aggressively funded research agenda. Its research focus is comprehensive, targeting the understanding of disease causes, the development of biomarkers for earlier diagnosis, and the creation of new therapeutic interventions to slow or stop progression. Key scientific priorities include investigating the role of the protein alpha-synuclein, exploring genetic links like the LRRK2 gene, understanding neuroinflammation, and advancing treatments for debilitating motor and non-motor symptoms. The foundation places a major emphasis on translational research, actively working to de-risk projects for the biopharmaceutical industry and facilitating clinical trials through initiatives like the Parkinson's Progression Markers Initiative.

Major initiatives and programs

A flagship program is the Parkinson's Progression Markers Initiative, a landmark observational clinical study launched in 2010 to identify biomarkers of disease progression. Other significant initiatives include the Fox Investigation for New Discovery of Biomarkers consortium, which seeks fluid-based biomarkers, and the Aligning Science Across Parkinson's global research collaboration. The foundation runs targeted funding programs such as the Ken Griffin Alpha-synuclein Imaging Competition to advance diagnostic tools. It also maintains a robust clinical trial recruitment platform, Fox Trial Finder, connecting volunteers with studies, and provides extensive educational resources for patients and families through its online presence and partnerships with institutions like the Parkinson's Foundation.

Funding and financials

The organization is funded primarily through philanthropic donations from individuals, corporations, and foundations, including significant support from figures like Ken Griffin and the Sergey Brin Family Foundation. It has consistently directed a high percentage of its annual revenue directly to research programs, with administrative and fundraising costs kept low, a model that has earned it top ratings from charity evaluators like Charity Navigator. Since its inception, it has funded over $1.5 billion in research projects worldwide. Its financial strategy involves venture philanthropy tactics, making staged investments in research projects and forming partnerships with entities like the National Institutes of Health and biotech companies to leverage additional funding and expertise.

Impact and achievements

The foundation is credited with transforming the landscape of Parkinson's disease research by increasing funding, setting collaborative research agendas, and accelerating the pace of discovery. Its work has been instrumental in advancing the clinical development of therapies targeting genetic forms of Parkinson's, such as those related to the LRRK2 and GBA genes. The data from the Parkinson's Progression Markers Initiative, made openly available to the global research community, has become an indispensable resource, fueling hundreds of secondary studies. Its advocacy efforts have also helped secure increased federal research funding through the National Institutes of Health and the Department of Defense.

Leadership and organization

The foundation is led by its founder, Michael J. Fox, who serves as a passionate public advocate and chairman of the board of directors. Co-founder Deborah W. Brooks serves as chief executive officer, bringing strategic management from her background in finance. The board includes leaders from business, science, and philanthropy, such as John D. Diekman and Michael D. Ehlers. The scientific direction is guided by a world-renowned team of researchers and a staff of PhD scientists who manage the grant portfolio. The organization operates from its headquarters in New York City and collaborates with an extensive international network of investigators at academic centers, including The Michael J. Fox Foundation for Parkinson's Research (United Kingdom) and research institutes across Europe and Asia.

Category:Medical and health organizations based in New York City Category:Parkinson's disease organizations Category:Organizations established in 2000